Biomaven, Injecting hyaluronidase may be OK for an acute indication, but for a chronic condition requiring daily injections for a lifetime like diabetes, I can't see the FDA signing off on that concept. Hyaluronidase breaks down connective tissue, in effect 'loosening' it up for better drug absorption, but it's hard to see that being approved for long term use.
A formulation containing EDTA doesn't seem like a great idea either from a long term safety standpoint. I think Biodel will have their hands full getting Viaject approved.
Market Data 
Markets 
AI
